Aviragen Therapeutics (AVIR) Tops Q2 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• Morgan Stanley Downgrades Kureha Corp (4023:JP) to Underweight
• Deutsche Bank Upgrades Kingfisher Plc. (KGF:LN) (KGFHY) to Hold